Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Actions01:26

Antibody Actions

979
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
979
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

296
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
296
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

421
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
421
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

767
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
767
Antimicrobial Proteins01:23

Antimicrobial Proteins

751
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
751

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cytosolic class I small heat shock protein, RcHSP17.8, of Rosa chinensis confers resistance to a variety of stresses to Escherichia coli, yeast and Arabidopsis thaliana.

Plant, cell & environment·2009
Same author

Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.

Neurochemistry international·2009
Same author

[Clinical features of interstitial pneumonitis due to interferon alpha therapy for chronic hepatitis C].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2009
Same author

Anti-hypoxic activity of the ethanol extract from Portulaca oleracea in mice.

Journal of ethnopharmacology·2009
Same author

[Effects of artemether and dihydroarteannuin on mouse model of scleroderma].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2009
Same author

Astragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats.

European journal of pharmacology·2009
Same journal

Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome.

Cell host & microbe·2026
Same journal

Predicting antimicrobial resistance for precision medicine.

Cell host & microbe·2026
Same journal

Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods.

Cell host & microbe·2026
Same journal

Single-cell detection and quantification of the microbiota by MicFLY.

Cell host & microbe·2026
Same journal

Suppression of host salicylic acid defense by a phloem-colonizing pathogen effector in citrus Huanglongbing.

Cell host & microbe·2026
Same journal

CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.

Cell host & microbe·2026
See all related articles

Related Experiment Video

Updated: May 15, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.7K

QDS pathoblockers target and lock α-hemolysin.

Yanan Wang1, Min Li2

  • 1Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Cell Host & Microbe
|April 10, 2025
PubMed
Summary
This summary is machine-generated.

Quinoxalinediones show promise in treating Staphylococcus aureus lung infections. These compounds work by inhibiting alpha-hemolysin, a key virulence factor, offering a new therapeutic strategy for bacterial pneumonia.

More Related Videos

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

10.6K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

14.9K

Related Experiment Videos

Last Updated: May 15, 2025

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.7K
Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
07:47

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases

Published on: January 1, 2016

10.6K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag
08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

14.9K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Staphylococcus aureus is a significant human pathogen.
  • Increasing antibiotic resistance in S. aureus poses a major public health threat.
  • S. aureus is a common cause of bacterial pneumonia.

Purpose of the Study:

  • To identify novel therapeutic strategies against S. aureus infections.
  • To investigate the potential of quinoxalinediones as anti-S. aureus agents.
  • To explore the mechanism of action for quinoxalinedione-mediated S. aureus inhibition.

Main Methods:

  • In vitro assays to assess bacterial growth inhibition.
  • In vivo models of S. aureus lung infection.
  • Analysis of alpha-hemolysin activity and expression.
  • Pharmacokinetic and pharmacodynamic studies of quinoxalinediones.

Main Results:

  • Quinoxalinediones demonstrated significant reduction in S. aureus lung infection burden in vivo.
  • The compounds were found to inhibit the activity of alpha-hemolysin.
  • No significant toxicity was observed at therapeutic concentrations.

Conclusions:

  • Quinoxalinediones represent a promising new class of therapeutics for S. aureus pneumonia.
  • Inhibition of alpha-hemolysin is a viable strategy to combat S. aureus infections.
  • Further development of quinoxalinediones could provide an alternative to conventional antibiotics.